These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24781826)
21. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620 [TBL] [Abstract][Full Text] [Related]
22. Using recombinant DNA technology for the development of live-attenuated dengue vaccines. Lee HC; Butler M; Wu SC Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189 [TBL] [Abstract][Full Text] [Related]
24. Dengue determinants: Necessities and challenges for universal dengue vaccine development. Hussain Z; Rani S; Ma F; Li W; Shen W; Gao T; Wang J; Pei R Rev Med Virol; 2023 Mar; 33(2):e2425. PubMed ID: 36683235 [TBL] [Abstract][Full Text] [Related]
25. Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? Lam JH; Ong LC; Alonso S Expert Rev Vaccines; 2016; 15(4):483-95. PubMed ID: 26508565 [TBL] [Abstract][Full Text] [Related]
26. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Wichmann O; Vannice K; Asturias EJ; de Albuquerque Luna EJ; Longini I; Lopez AL; Smith PG; Tissera H; Yoon IK; Hombach J Vaccine; 2017 Oct; 35(42):5535-5542. PubMed ID: 28893477 [TBL] [Abstract][Full Text] [Related]
27. T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques. Sun P; Jani V; Johnson A; Cheng Y; Nagabhushana N; Williams M; Morrison BJ; Defang G Vaccine; 2021 Dec; 39(51):7510-7520. PubMed ID: 34823910 [TBL] [Abstract][Full Text] [Related]
36. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. Gessner BD; Wilder-Smith A Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020 [TBL] [Abstract][Full Text] [Related]
37. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647 [TBL] [Abstract][Full Text] [Related]
38. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997 [TBL] [Abstract][Full Text] [Related]
39. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K mBio; 2020 Apr; 11(2):. PubMed ID: 32265332 [TBL] [Abstract][Full Text] [Related]
40. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine. Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]